Agenus (AGEN) Competitors $4.34 +0.06 (+1.28%) Closing price 03:59 PM EasternExtended Trading$4.32 -0.02 (-0.46%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock AGEN vs. EBS, LXRX, XOMA, CBIO, VNDA, CDXS, IRWD, SGMO, ACHV, and DOMHShould you be buying Agenus stock or one of its competitors? The main competitors of Agenus include Emergent Biosolutions (EBS), Lexicon Pharmaceuticals (LXRX), XOMA Royalty (XOMA), Crescent Biopharma (CBIO), Vanda Pharmaceuticals (VNDA), Codexis (CDXS), Ironwood Pharmaceuticals (IRWD), Sangamo Therapeutics (SGMO), Achieve Life Sciences (ACHV), and Dominari (DOMH). These companies are all part of the "biotechnology" industry. Agenus vs. Its Competitors Emergent Biosolutions Lexicon Pharmaceuticals XOMA Royalty Crescent Biopharma Vanda Pharmaceuticals Codexis Ironwood Pharmaceuticals Sangamo Therapeutics Achieve Life Sciences Dominari Emergent Biosolutions (NYSE:EBS) and Agenus (NASDAQ:AGEN) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, media sentiment, risk, institutional ownership, valuation, earnings and analyst recommendations. Do analysts recommend EBS or AGEN? Emergent Biosolutions presently has a consensus price target of $14.33, suggesting a potential upside of 89.47%. Agenus has a consensus price target of $14.50, suggesting a potential upside of 233.72%. Given Agenus' higher probable upside, analysts plainly believe Agenus is more favorable than Emergent Biosolutions.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Emergent Biosolutions 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Agenus 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50 Which has more volatility & risk, EBS or AGEN? Emergent Biosolutions has a beta of 2.04, meaning that its stock price is 104% more volatile than the S&P 500. Comparatively, Agenus has a beta of 1.44, meaning that its stock price is 44% more volatile than the S&P 500. Does the media favor EBS or AGEN? In the previous week, Emergent Biosolutions had 5 more articles in the media than Agenus. MarketBeat recorded 9 mentions for Emergent Biosolutions and 4 mentions for Agenus. Emergent Biosolutions' average media sentiment score of 1.00 beat Agenus' score of 0.52 indicating that Emergent Biosolutions is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Emergent Biosolutions 5 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Agenus 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders hold more shares of EBS or AGEN? 78.4% of Emergent Biosolutions shares are owned by institutional investors. Comparatively, 61.5% of Agenus shares are owned by institutional investors. 1.2% of Emergent Biosolutions shares are owned by company insiders. Comparatively, 5.5% of Agenus shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Is EBS or AGEN more profitable? Emergent Biosolutions has a net margin of 16.38% compared to Agenus' net margin of -167.52%. Emergent Biosolutions' return on equity of 24.63% beat Agenus' return on equity.Company Net Margins Return on Equity Return on Assets Emergent Biosolutions16.38% 24.63% 8.97% Agenus -167.52%N/A -81.04% Which has preferable earnings & valuation, EBS or AGEN? Emergent Biosolutions has higher revenue and earnings than Agenus. Agenus is trading at a lower price-to-earnings ratio than Emergent Biosolutions, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEmergent Biosolutions$1.04B0.39-$190.60M$2.453.09Agenus$103.46M1.34-$227.21M-$7.15-0.61 SummaryEmergent Biosolutions beats Agenus on 13 of the 16 factors compared between the two stocks. Get Agenus News Delivered to You Automatically Sign up to receive the latest news and ratings for AGEN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AGEN vs. The Competition Export to ExcelMetricAgenusMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$138.43M$3.16B$5.78B$9.92BDividend YieldN/A2.28%6.67%4.52%P/E Ratio-0.6121.1175.6726.67Price / Sales1.34463.83554.40206.13Price / CashN/A45.1137.1158.92Price / Book-0.339.8611.446.09Net Income-$227.21M-$53.47M$3.28B$266.14M7 Day Performance3.95%2.79%0.78%0.22%1 Month Performance-17.86%8.49%7.07%4.08%1 Year Performance-13.10%13.61%59.61%23.89% Agenus Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AGENAgenus4.0279 of 5 stars$4.35+1.3%$14.50+233.7%-11.5%$138.43M$103.46M-0.61440EBSEmergent Biosolutions4.826 of 5 stars$8.29-1.3%$14.33+73.0%+2.9%$442.01M$1.04B3.382,420Positive NewsAnalyst ForecastLXRXLexicon Pharmaceuticals2.1167 of 5 stars$1.10-4.3%$3.23+193.2%-34.4%$399.74M$31.08M-3.33140Analyst ForecastXOMAXOMA Royalty3.7709 of 5 stars$32.47-0.7%$69.50+114.0%+24.6%$392.56M$28.49M-20.9510Positive NewsCBIOCrescent Biopharma3.5594 of 5 stars$14.40+1.8%$25.60+77.8%N/A$281.52MN/A-0.4150News CoverageVNDAVanda Pharmaceuticals4.07 of 5 stars$4.73+0.6%$16.50+248.8%-8.7%$279.50M$198.77M-4.19290CDXSCodexis3.8923 of 5 stars$2.73+0.4%$11.00+302.9%-14.5%$246.43M$57.16M-3.29250Positive NewsIRWDIronwood Pharmaceuticals4.2683 of 5 stars$1.32flat$4.94+274.2%-77.8%$214.41M$351.41M-26.39220SGMOSangamo Therapeutics2.1451 of 5 stars$0.52-3.9%$4.50+765.4%-33.6%$156.89M$81.71M-1.79480News CoverageAnalyst ForecastACHVAchieve Life Sciences2.2786 of 5 stars$2.98-5.7%$14.67+392.2%-34.4%$152.28MN/A-2.0420Positive NewsShort Interest ↑DOMHDominari0.6514 of 5 stars$6.42+2.7%N/A+226.4%$99.77M$18.15M-2.714 Related Companies and Tools Related Companies Emergent Biosolutions Alternatives Lexicon Pharmaceuticals Alternatives XOMA Royalty Alternatives Crescent Biopharma Alternatives Vanda Pharmaceuticals Alternatives Codexis Alternatives Ironwood Pharmaceuticals Alternatives Sangamo Therapeutics Alternatives Achieve Life Sciences Alternatives Dominari Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AGEN) was last updated on 9/5/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredOne tiny company just cracked Google’s $19B problemFor decades, this “AI metal” was trapped in labs, too slow and expensive to ever reach mass production. The...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Agenus Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Agenus With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AGEN Stock Alerts